心血管热门文献

心血管外文指南

骨质疏松中文指南

骨质疏松外文指南

前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中二级预防中的临床应用专家共识
摘要:近30年来,我国卒中的患病率和发病率逐年攀升,已成为我国全因死亡的首要疾病[1-2].2013年对全国31个省份进行的一项入户调查显示,我国卒中患病率为1115/10万人年,发病率为247/10万人年,死亡率为115/10万人年,在各卒中亚型中,缺血性卒中约占70%[3].缺血性卒中复发率高,流行病学数据显示中国缺血性卒中患者1年内再发心脑血管事件发生率达11.8%,故有效的二级预防至关重要[4].降脂治疗是卒中二级预防的基石之一.强化降低胆固醇预防卒中(Stroke Prevention by Aggressive Reduction in Cholesterol Levels,SPARCL)研究显示,对于非心源性缺血性卒中或TIA的患者,强化阿托伐他汀(80?mg/d)治疗5年,可使患者卒中复发相对危险降低16%(HR?0.84, 95%CI?0.71~0.99,P=0.03)
中国心血管病风险评估和管理指南 中国心血管病风险评估和管理指南
摘要:心血管病是造成我国居民死亡和疾病负担的首要病因,心血管病防控形势严峻.心血管病风险评估和危险因素管理是预防心血管病的重要基础.根据国内外最新的流行病学和防治证据,本指南着重介绍了我国开展心血管病风险评估的指导方案,包括心血管病10年风险和终生风险评估的流程,风险分层依据和风险评估工具的使用.针对心血管病的一级预防,本指南进一步介绍了生活方式干预的基本措施,血压、血脂、血糖管理的基本原则等内容.本指南的实施有助于指导我国心血管病风险评估和相关危险因素管理,推进基层心血管病预防工作.
动脉粥样硬化性心血管疾病的降胆固醇治疗及进展
摘要:动脉粥样硬化性心血管疾病(atherosclerotic cardi-ovascular disease,ASCVD)包括冠心病、缺血性脑卒中、间歇性跛行及症状性颈动脉狭窄. ASCVD首次发作就存在较高的致死、致残风险. 导致ASCVD的最主要危险因素为吸烟、高血压、血脂异常及糖尿病,积极有效地干预和控制这些危险因素已被发达国家证实能够大幅度降低心血管死亡率.
前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中二级预防中的临床应用专家共识
摘要:近30年来,我国卒中的患病率和发病率逐年攀升,已成为我国全因死亡的首要疾病[1-2].2013年对全国31个省份进行的一项入户调查显示,我国卒中患病率为1115/10万人年,发病率为247/10万人年,死亡率为115/10万人年,在各卒中亚型中,缺血性卒中约占70%[3].缺血性卒中复发率高,流行病学数据显示中国缺血性卒中患者1年内再发心脑血管事件发生率达11.8%,故有效的二级预防至关重要[4].降脂治疗是卒中二级预防的基石之一.强化降低胆固醇预防卒中(Stroke Prevention by Aggressive Reduction in Cholesterol Levels,SPARCL)研究显示,对于非心源性缺血性卒中或TIA的患者,强化阿托伐他汀(80?mg/d)治疗5年,可使患者卒中复发相对危险降低16%(HR?0.84, 95%CI?0.71~0.99,P=0.03)[5].在SPARCL研究的事后分析中,与LDL-C水平降幅度<50%相比,应用阿托伐他汀使LDL-C水平降幅超过50%的患者,其卒中复发风险显著降低31%;
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
摘要:In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein
2018 Guidelines for the management of dyslipidemia.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force
Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.
摘要:Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are undiagnosed. Herein, we provide an update of the 2014 Canadian Cardiovascular Society position statement on FH addressing the need for case identification, prompt recognition, and treatment with statins and ezetimibe, and cascade family screening.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
摘要:An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia:
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARY
摘要:Objective: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs).
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.
Consensus statement on the management of dyslipidaemias in adults.
糖尿病患者骨折风险管理的中国专家共识
摘要:1型和2型糖尿病患者的骨质量受损,骨折风险升高.由于糖尿病患者的骨密度不一定下降,而且各种糖尿病治疗有可能对骨骼产生影响,给临床上如何管理糖尿病患者的骨折风险带来了挑战.中华医学会骨质疏松和骨矿盐疾病分会、中华医学会内分泌学分会、中华医学会糖尿病学分会和中国医师协会内分泌代谢科医师分会共同组织专家,在充分汇总复习文献的基础上,就如何在糖尿病患者中评估骨折风险、实施骨质疏松防治、合理使用各类降糖药物等问题达成共识.
糖尿病患者骨折风险管理的中国专家共识
摘要:1型和2型糖尿病患者的骨质量受损,骨折风险升高.由于糖尿病患者的骨密度不一定下降,而且各种糖尿病治疗有可能对骨骼产生影响,给临床上如何管理糖尿病患者的骨折风险带来了挑战.中华医学会骨质疏松和骨矿盐疾病分会、中华医学会内分泌学分会、中华医学会糖尿病学分会和中国医师协会内分泌代谢科医师分会共同组织专家,在充分汇总复习文献的基础上,就如何在糖尿病患者中评估骨折风险、实施骨质疏松防治、合理使用各类降糖药物等问题达成共识.
骨质疏松的影像学与骨密度诊断专家共识
摘要:随着我国进入老年化社会,骨质疏松症已经成为严重威胁老年人健康的常见疾病之一.骨质疏松表现为骨量减少,易发生骨折,影像学检查包括X线片、CT、MRI、核医学检查和骨密度测量,在骨质疏松症的防治中发挥重要作用.骨质疏松症防治涉及多学科和多专业合作,但目前缺乏统一的共识,影响学科发展和规范临床服务,为此由来自放射、骨科、内分泌、影像技术和核医学专业专家组成的共识专家组,在充分复习国际指南、共识、文献以及国内最新研究成果的基础上,结合我国医疗实际情况,针对骨质疏松的影像学和骨密度检查技术、诊断标准和鉴别诊断形成共识,为临床医务工作者在骨质疏松的影像学与骨密度临床应用方面提供科学、具体的指导,促进我国骨质疏松的影像学与骨密度诊断规范化发展.
下肢关节周围骨质疏松性骨折诊疗与康复专家共识
摘要:下肢关节周围骨质疏松性骨折好发于老年人,可带来运动功能丢失、骨缺损、内固定丢失等风险.区别于常规骨折的术后康复,下肢关节周围骨折要求良好的手术与康复治疗以恢复运动功能,而骨质疏松性骨折要求充分的医患沟通与个性化康复以规避内固定丢失风险.本共识着眼于下肢关节周围骨质疏松性骨折的特殊性,旨在平衡康复训练要求与安全性,促进下肢关节周围骨质疏松性骨折个性化诊疗与康复的推广普及.
中国骨质疏松性骨折围手术期处理专家共识(2018)
摘要:骨质疏松性骨折是继发于骨质疏松症、低能量暴力导致的骨折.伴随我国进入老年社会,骨质疏松性骨折发病率逐年快速升高,逐渐成为骨质疏松症患者的首发症状和就诊原因.骨质疏松性骨折多为高龄老年患者,合并内科基础疾病较多,病情复杂,手术风险显著增加;患者骨量下降,多为粉碎性骨折,内固定失败率相对较高;骨质疏松性骨折愈合缓慢,甚至不愈合,容易再发骨折.围手术期处理是骨质疏松性骨折手术治疗的最重要环节,决定着治疗的成败,其处理原则、处理方法与一般常见骨折有共同之处,但也有特殊要点,推动骨质疏松性骨折标准化、规范化治疗是当下亟待解决的问题.因此,中华医学会骨科学分会青年骨质疏松学组召集了国内骨质疏松性骨折相关研究领域的专家,结合国内外最新的循证医学证据和临床经验,撰写了本共识,旨在为骨质疏松性骨折围手术期的处理提供一个适合国情且规范标准、容易操作的治疗方案,有效提升我国骨质疏松性骨折的治疗效果,改善患者预后.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
摘要:Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods:
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE
摘要:Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors,